Quest CEO
This article was originally published in The Rose Sheet
Executive Summary
Charles Knott tapped as chairman and chief executive of Quest, succeeding Paul Drechsler, a 25-year veteran of parent company Imperial Chemical Industries, ICI reports March 28. Knott joins the fragrance, flavors and food ingredients business of ICI from the company's subsidiary National Starch, where he served as president and chief operating officer of the adhesives and industrial starch manufacturer. During his tenure at National Starch, the division's Asian sales grew by 70% and profits by 170% during a six-year period. Knott will transition into his new role at Quest over the next month...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.